In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Harrow Health. The company’s shares closed last Friday at $45.43.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Knickerbocker is a 5-star analyst with an average return of 28.1% and a 62.14% success rate. Knickerbocker covers the Healthcare sector, focusing on stocks such as Harrow Health, Celcuity, and MiMedx Group.
Currently, the analyst consensus on Harrow Health is a Strong Buy with an average price target of $65.00, representing a 43.08% upside. In a report released today, Lake Street also maintained a Buy rating on the stock with a $70.00 price target.
The company has a one-year high of $59.23 and a one-year low of $20.85. Currently, Harrow Health has an average volume of 618.1K.
Read More on HROW:
/Semiconductor%20by%20Gorodenkoff%20via%20Shutterstock.jpg)
/An%20image%20of%20a%20Tesla%20humanoid%20robot%20in%20front%20of%20the%20company%20logo%20Around%20the%20World%20Photos%20via%20Shutterstock.jpg)
